

WOMEN LIVING WITH HIV

GSK

While HIV affects everyone differently, women often face particular challenges.¹ Understanding the relationship of being a woman living with HIV and your current HIV treatment regimen may have implications on your decisions now and in the future.²

There are options, so why not ask if a 2-drug regimen might be a good choice for you?³

The more you know about your treatment the better.



**IS YOUR
CURRENT HIV
TREATMENT REGIMEN
THE RIGHT OPTION
FOR YOU?**

EXPLORE THE QUESTIONS BELOW

Ask your doctor about your current HIV treatments – you can use this resource alongside the general question guide.

LIVING WITH HIV AS A WOMAN


- How does HIV affect my reproductive health?
- What birth control options are available for HIV+ women? Does birth control interact with my HIV medications?
- Does my HIV treatment affect my menstruation?
- How can I best protect my partner from the risk of HIV transmission?

HIV AND PREGNANCY/BREASTFEEDING

- Does being pregnant make my HIV worse?
- What is the risk of HIV transmission to my baby during labour?
- Is my current treatment the best option for women who wish to become pregnant?
- Is it safe to take HIV medicines during pregnancy and/or breastfeeding?
- Can I breastfeed my baby, what are the risks of HIV transmission to my baby?

HIV AND MENOPAUSE


- Does HIV or HIV treatment affect menopause?
- Are there any considerations during menopause for women living with HIV?



Tick off the questions that are important to you – add some questions of your own!

**FOR MORE INFORMATION ON 2-DRUG REGIMEN
AND TIVICAY + LAMIVUDINE SCAN THE QR CODES**

OR VISIT WWW.2DR.CO.NZ



Abbreviation: HIV, human immunodeficiency virus.

References: 1. HIVgov. HIV Basics, HIV and women's health issues. Updated 15th June 2022. Available from: <https://www.hiv.gov/hiv-basics/staying-in-hiv-care/other-related-health-issues/womens-health-issues/> (accessed 23 March 2023). 2. European AIDS Clinical Society (EACS Guidelines). Initial combination regimen for ART-naïve adults, October 2022 (version 11.1). Available at: https://www.eacsociety.org/media/guidelines-11.1_final_09-10.pdf (accessed 03 March 2023). 3. Chawla A, et al. *Infect Dis Ther* 2018 Jun;7(2):183-195.

TIVICAY (dolutegravir sodium), 50 mg film-coated tablets, is an integrase inhibitor, used for the treatment of Human Immunodeficiency Virus (HIV) infection in combination with other anti-HIV agents in adults and children over 12 years of age and weighing 40 kg or more. Tivicay is a funded medicine; Special Authority criteria apply. **DOVATO** (dolutegravir and lamivudine) is a film coated tablet containing 50 mg of dolutegravir (as dolutegravir sodium) and 300 mg of lamivudine, which is used for the treatment of Human Immunodeficiency Virus (HIV) infection in adults and adolescents (from 12 years of age weighing at least 40 kg) who have no known or suspected resistance to either antiretroviral component. Dolutegravir is an integrase inhibitor active against Human Immunodeficiency Virus (HIV). Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) and is a potent, selective inhibitor of HIV-1 and HIV-2. Dovato is not funded and is not supplied in New Zealand, this treatment option is available as separate medicines: Tivicay + Lamivudine. **TIVICAY and DOVATO are both prescription medicines. Tivicay and Dovato have risks and benefits and should only be prescribed by a doctor experienced in treating HIV. Ask your doctor if TIVICAY or DOVATO is right for you. Use strictly as directed.** If you have concerns, symptoms continue or if you have side effects, see your doctor, pharmacist or healthcare professional. Normal doctor's consultation fees apply. You can view full Consumer Medicine Information at www.medsafe.govt.nz. Trademarks are owned by or licensed to the Viiv Healthcare group of companies.

©2023 Viiv Healthcare group of companies or its licensor. Marketed on behalf of Viiv Healthcare by GlaxoSmithKline NZ Limited, Auckland.

Adverse events involving Viiv Healthcare products should be reported to Viiv Healthcare Medical Information on 0800 808 500. Date of Approval: **May 2023** and Date of Expiry: **May 2025**. TAPS-NP19321 PM-NZ-2DR-WCNT-230002.

 **Tivicay + lamivudine**
dolutegravir

A COMPLETE REGIMEN